EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseOpen Access · CC BY-NC-ND 4.0

Network meta‐analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence

Francesca Salani iD, Guglielmo Vetere iD, Daniele Rossini, Virginia Genovesi, Martina Carullo, Linda Bartalini, Valentina Massa, Laura Bernardini, Miriam Caccese, Silvia Cesario, Jessica Graziani, Giada Grelli und 4 weitere

Liver International · 2024

DOI: 10.1111/liv.16047 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Liver International, 2024. Verfasst von Francesca Salani und 15 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research and New Technologies in Medicine and Surgery Department, Pisa University, Pisa, Italy. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The best adjuvant chemotherapy for resected biliary tract cancer (BTC) is under debate, with capecitabine supported by weak evidence. Aim of this network meta‐analysis is to estimate the efficacy of different phase II/III regimens, comparing monotherapies (gemcitabine or fluoropyrimidines) head‐to‐head, against observation and combination regimens.

Methods

A comprehensive literature search was conducted on PubMed and EMBASE for phase II/III randomized clinical trials (RCTs) available as of December 2023, reporting hazard ratios (HRs) of overall survival (OS) and event‐free survival (EFS). A frequentist framework employing a random‐effects model was applied; treatment rankings were outlined according to P ‐score, based on direct and indirect evidence. Exploratory subgroup analyses for OS were also performed (primary site, resected margin status and nodal involvement).

Results

Six RCTs (1979 total patients) were identified. Fluoropyrimidine monotherapy showed significantly better OS (HR .84 [.72–.97]) and EFS (HR .79 [.69–.91]) than observation, as any monotherapy did (HR .84 [.74–.96]; HR .79 [.70–.89]). In the head‐to‐head comparison for OS, only S1 confirmed to be superior to observation alone (HR .69 [.49–.98]) while fluoropyrimidines achieved the best P score (.81), similarly to any monotherapy (0.92). Combinations failed to prove superior to monotherapies with respect both to OS and EFS. Subgroup analyses were inconclusive due to results' inconsistency and limited sample size.

Conclusions

Our work confirmed that adjuvant chemotherapy grants OS and EFS benefit for resected BTC patients. Fluoropyrimidines appeared the most effective option, confirming capecitabine as the preferred choice for the Western population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemotherapy, AdjuvantClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDeoxycytidineGemcitabineRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

adjuvant chemotherapybiliary tract cancersnetwork meta‐analysisprognosis

Substanzen

CapecitabineDeoxycytidineGemcitabine

Autor:innen und Institutionen

  • Translational Research and New Technologies in Medicine and Surgery Department, Pisa University, Pisa, Italy.
  • Sant'Anna School of Advanced Studies, Pisa, Italy.
  • Unit of Medical Oncology, Università degli Studi di Pisa Scuola di Medicina, Azienda Ospedaliera Univeristaria Pisana, Pisa, Italy.
  • Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
  • Unit of Medical Oncology, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.

ORCID-Profile: Francesca Salani, Guglielmo Vetere

Zitieren

APA

Salani, F., Vetere, G., Rossini, D., Genovesi, V., Carullo, M., Bartalini, L., Massa, V., Bernardini, L., Caccese, M., Cesario, S., Graziani, J., Grelli, G., Mangogna, F., Vivaldi, C., Masi, G., & Fornaro, L. (2024). Network meta‐analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence. Liver International. https://doi.org/10.1111/liv.16047

Vancouver

Salani F, Vetere G, Rossini D, Genovesi V, Carullo M, Bartalini L, et al. Network meta‐analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence. Liver International. 2024. doi:10.1111/liv.16047

BibTeX
@article{Salani2024,
  author = {Salani, Francesca and Vetere, Guglielmo and Rossini, Daniele and Genovesi, Virginia and Carullo, Martina and Bartalini, Linda and Massa, Valentina and Bernardini, Laura and Caccese, Miriam and Cesario, Silvia and Graziani, Jessica and Grelli, Giada and Mangogna, Francesco and Vivaldi, Caterina and Masi, Gianluca and Fornaro, Lorenzo},
  title = {Network meta‐analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.16047}
}
Kostenlos starten →